AbstractInhibition of tumor necrosis factor-α converting enzyme (TACE) is a widespread objective in the search for disease modifying agents to combat rheumatoid arthritis and other autoimmune diseases. Until recently, most of the inhibitors in the literature have shown concomitant activity against the related matrix metalloproteinases (MMPs), producing undesired side effects. Here we describe the successful search for a TACE selectivity mechanism. We built a homology model based on the crystal structure of the related snake venom protein atrolysin. Comparison of the model with crystal structures of MMPs suggested a uniquely shaped S1′ pocket that might be exploited for selectivity. A novel γ-lactam scaffold [1] was used to explore the activ...
Tumour necrosis factor-α (TNF-α) converting enzyme (TACE) is a membrane-anchored, multiple-domain zi...
TNF-α converting enzyme (TACE/ADAM-17) is a type I membrane-bound metalloproteinase that processes t...
TNF-alpha neutralising agents such as Infliximab (Remicade), Etanercept (Enbrel) and the IL-1 recept...
<div><p>Tumor necrosis factor-α (TNF-α) converting enzyme (TACE) has been considered one of the prin...
AbstractTNF-α converting enzyme (TACE; ADAM-17) is a membrane-bound disintegrin metalloproteinase th...
Tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE/ADAM-17) is responsible for the rele...
Tumor necrosis factor-alpha converting enzyme (TACE) is considered as a pro-inflammatory cytokine wh...
Tumor necrosis factor (TNF)- is a well validated therapeutic target for the treatment of rheumatoid...
We previously reported that full-length tissue inhibitor of metallo-proteinase-3 (TIMP-3) and its N-...
We previously reported that full-length tissue inhibitor of metallo-proteinase-3 (TIMP-3) and its N-...
Tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE/ADAM-17) is responsible for the rele...
Tumor necrosis factor (TNF)-alpha is a well validated therapeutic target for the treatment of rheuma...
Tumor necrosis factor-alpha converting enzyme (TACE) is an ADAM (a disintegrin and metalloproteinase...
TNF-α converting enzyme (TACE; ADAM-17) is a membrane-bound disintegrin metalloproteinase that proce...
Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a dual inhibitor of the matrix metalloproteinase...
Tumour necrosis factor-α (TNF-α) converting enzyme (TACE) is a membrane-anchored, multiple-domain zi...
TNF-α converting enzyme (TACE/ADAM-17) is a type I membrane-bound metalloproteinase that processes t...
TNF-alpha neutralising agents such as Infliximab (Remicade), Etanercept (Enbrel) and the IL-1 recept...
<div><p>Tumor necrosis factor-α (TNF-α) converting enzyme (TACE) has been considered one of the prin...
AbstractTNF-α converting enzyme (TACE; ADAM-17) is a membrane-bound disintegrin metalloproteinase th...
Tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE/ADAM-17) is responsible for the rele...
Tumor necrosis factor-alpha converting enzyme (TACE) is considered as a pro-inflammatory cytokine wh...
Tumor necrosis factor (TNF)- is a well validated therapeutic target for the treatment of rheumatoid...
We previously reported that full-length tissue inhibitor of metallo-proteinase-3 (TIMP-3) and its N-...
We previously reported that full-length tissue inhibitor of metallo-proteinase-3 (TIMP-3) and its N-...
Tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE/ADAM-17) is responsible for the rele...
Tumor necrosis factor (TNF)-alpha is a well validated therapeutic target for the treatment of rheuma...
Tumor necrosis factor-alpha converting enzyme (TACE) is an ADAM (a disintegrin and metalloproteinase...
TNF-α converting enzyme (TACE; ADAM-17) is a membrane-bound disintegrin metalloproteinase that proce...
Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a dual inhibitor of the matrix metalloproteinase...
Tumour necrosis factor-α (TNF-α) converting enzyme (TACE) is a membrane-anchored, multiple-domain zi...
TNF-α converting enzyme (TACE/ADAM-17) is a type I membrane-bound metalloproteinase that processes t...
TNF-alpha neutralising agents such as Infliximab (Remicade), Etanercept (Enbrel) and the IL-1 recept...